Thread by @SnapLaugh

BIOCON
Q4FY20 - Muted growth of 6%,revenue 1644cr ,one time covid impact on Biologics business
Full year ,strong performance, biologics grew 29%,small molecules 18% ,research 10%.
Biologics to recover inQ1 & normalize in Q2
@kiranshaw @Bioconlimited #biosimilars

Pegfilgrastim,Fulphila commercialized in Australia & Canada

USFDA accepted license application for Bevacizumab

Insulin facility in Malaysia received EIR from USFDA

Indian govt allowed to test Itolizumab in mod to severe Covid ,initial result appear promisin
#COVID19 #biocon

Expect US launch of Insulin Glargine( Semglee) in midCY20 .

Ogivri & Semglee(Insulin Glargine) commercialized in Australia earlier this financial year

Dedicated Covid 19 testing center set up in Bangalore ,supply and development of covid 19 testing kits ,tests are being offered free of costs

Syngene started #Covid_19 testing to support govt hospitals in Bengaluru,syngene scientists are involved in research of vaccine
#COVID

Biocon has entered China,worlds 2nd largest pharma market, by forging a partnership with China medical system holdings

Greenfield project in Visakapatnam to cater to anticipated demand in small molecules APIs business

#COVID #CoronaVirus #china #Wuhan #biocon @Bioconlimited

Biocon launched its 2nd biosimilar Ogivri,Trastuzumab developed with Mylan in US in Dec2019

1st company from India to have commercialized 2 biosimilars in US,other Fulphila

Look fwd to approval & launch of Semglee

@Bioconlimited @SyngeneIntl @kiranshaw #biocon #biosimilars

Key milestone in fy20 ,pvt equity investment of US dollar 75 million by Active Pine LLP, affiliate of True north fund in Biocon biologics for 2.44% stake at equity value of US$ 3 billion & EV value of US$ 3.5 Billion

#truenorthfund #activpinellp @Bioconlimited @SyngeneIntl

unroll
@threadreaderapp